10q10k10q10k.net
Inmune Bio, Inc.

Inmune Bio, Inc.INMBEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Inmune Bio, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies to address unmet medical needs, including hard-to-treat hematologic malignancies, solid tumors, and neurodegenerative diseases such as Alzheimer's. Its lead product candidates modulate the innate immune system to improve patient outcomes across global key markets.

Q3 2025Q2 2025Q1 2025Q3 2024Q2 2024Q1 2024

Revenue

$0

Gross Profit

N/A

Operating Profit

$-24.6M

Net Profit

$-24.5M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-1.05

Inmune Bio, Inc. Q2 FY2025 Financial Summary

Inmune Bio, Inc. reported revenue of $0 for Q2 FY2025, with a net profit of $-24.5M (down 151.0% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-24.5M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ2 FY2025

Inmune Bio, Inc. Quarterly Revenue & Net Profit History

Inmune Bio, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q3 FY2025$0—$-6.5MN/A
Q2 FY2025$0—$-24.5MN/A
Q1 FY2025$50.0K+257.1%$-9.7M-19478.0%
Q3 FY2024$0—$-12.1MN/A
Q2 FY2024$0—$-9.7MN/A
Q1 FY2024$14.0K-63.2%$-11.0M-78750.0%

Income Statement

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Revenue$14000$0$0$50000$0$0
YoY Growth-63.2%N/AN/A257.1%N/AN/A

Balance Sheet

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Assets$46.8M$52.5M$52.8M$37.8M$37.7M$33.4M
Liabilities$17.8M$15.4M$14.1M$8.1M$8.8M$8.0M
Equity$28.2M$36.3M$38.7M$29.7M$28.9M$25.4M

Cash Flow

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Operating CF$-7.5M$-7.9M$-7.0M$-6.8M$-7.4M$-5.4M